KIT and cancer: It is possible that this ER-ve SCLC plasticity is a feature of subsets of cancer cells, accounting for the observations that c-KIT knockdown effectively eliminates the 3D culture potential of primary mammary cells [35], whereas therapies targeting c-KIT in breast cancer patients have had limited success [51].